This site is intended for healthcare professionals
Micrograph of a prostate carcinoma with atypical mitosis rendered in green
HSPC: Navigating Risk and Management

Podcast series: HSPC Unlocked

Last updated: 18th Feb 2026
Published: 18th Feb 2026
Declaration of sponsorship: Astellas
HSPC: Navigating Risk and Management

Optimizing care and improving outcomes in hormone-sensitive prostate cancer

How can we optimize care for patients with non-metastatic (nm) or metastatic (m) hormone-sensitive prostate cancer (HSPC) in practice? Joined by expert guests, podcast series host Bertrand Tombal (Université catholique de Louvain and Cliniques universitaires, Brussels, Belgium) explores a range of topics, including:

  • Barriers and benefits to collaboration across multidisciplinary teams (MDTs)
  • Improving patient outcomes in high-risk biochemical recurrence (BCR)
  • Available approaches and emerging evidence in mHSPC

Access the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information (PI) for enzalutamide. Adverse event reporting can be found at the bottom of the page.

Listen to the series

How much do you know about optimizing care for people with non-metastatic (nm) or metastatic (m) hormone-sensitive prostate cancer (HSPC)? 
Take this quiz to find out. We’ll ask you the questions again after you’ve watched the HSPC Unlocked podcast series to see what you recall.

1. What is a key challenge in implementing multidisciplinary teams (MDTs) across nations?
2. Which of the following treatments is now recommended by guidelines for patients with high-risk biochemically recurrent (BCR) non-metastatic hormone-sensitive (nmHSPC) prostate cancer who are unsuitable for salvage radiation?
3. Which emerging target is under clinical investigation for metastatic hormone-sensitive prostate cancer (mHSPC)?

Unveiling HSPC care: Collaboration is key1-13

 

It is a multidisciplinary collaboration that really helps to keep the patient whole, even as they go through all of these therapies.
Alicia Morgans, MD

MA-MM-16214, December 2025

Bertrand Tombal disclosures: Investigator and paid advisor for Amgen, Astellas, Bayer, Ferring, Janssen, Myovant, Pfizer, and Sanofi.

Alicia Morgans disclosures: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Exelixis, Johnson & Johnson, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Sumitomo Pharma, Inc., Telix, and Tolmar.

Episode 1. Alicia Morgans joins Bertrand Tombal to discuss their in-clinic experience of real-time collaboration across the MDT, highlighting differences in care in the USA and Europe, and sharing examples of the important roles of members of the MDT, including geriatric oncologists and nurses.

This podcast series is sponsored by Astellas. This content includes information about investigational compounds that may be approved by regulatory agencies for specific indications, have been submitted to regulatory agencies for approval for specific indications, or are being studied in clinical trials and do not yet have a regulatory approval or authorization for a specific indication. Information about other potential uses of these products or investigational compounds is intended only for the purposes of medical education and is aimed at increasing the scientific knowledge of healthcare professionals (HCPs), to enhance medical practice and improve patient outcomes and should not be interpreted as intent to promote unapproved uses. Indications and availability of products discussed in this educational meeting may vary in different countries. Please refer to the local summary of product characteristics/prescribing information for details. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations, and company policies. In expert interviews, podcasts, and panel discussions, the views, thoughts, and opinions expressed belong solely to the speaker(s) and are subject to change without notice. This content is intended for HCPs only. Non-HCPs should not view this educational program and should exit the program as soon as possible.

References

  1. Willett, 2000. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. https://www.doi.org/10.1016/s0360-3016(99)00374-0
  2. Trotta, 2023. Safety of radiation therapy in patients with prostate cancer and inflammatory bowel disease: A systematic review. https://www.doi.org/10.1016/j.prro.2023.04.006
  3. Tilki, 2024. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II—2024 update: Treatment of relapsing and metastatic prostate cancer. https://www.doi.org/10.1016/j.eururo.2024.04.010
  4. Freedland, 2023. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. https://www.doi.org/10.1056/NEJMoa2303974
  5. Tsuboi, 2025. Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: A systematic review and meta-analysis of randomized controlled trials. https://www.doi.org/10.1016/j.euros.2025.01.001
  6. Brown, 2020. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. https://www.doi.org/10.1016/j.jbo.2020.100311
  7. Parker, 2022. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. https://www.doi.org/10.1371/journal.pmed.1003998
  8. Tsuboi, 2024. A systematic review and meta-analysis of the impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.1016/j.euo.2024.03.007
  9. Graham, 2023. Management of prostate cancer in older adults. https://www.doi.org/10.1200/edbk_390396
  10. Mori, 2022. Systemic therapies for metastatic hormone-sensitive prostate cancer: Network meta-analysis. https://www.doi.org/10.1111/bju.15507
  11. Bonneau, 2025. Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients. https://www.doi.org/10.1186/s12885-025-13961-z
  12. Smani, 2025. Advances in current treatment paradigms for metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.3390/jcm14082565
  13. Horlait, 2019. How multidisciplinary are multidisciplinary team meetings in cancer care? An observational study in oncology departments in Flanders, Belgium. https://www.doi.org/10.2147/jmdh.S196660

High-risk BCR: Uncovering better outcomes1-26

MA-MM-16679, January 2026

Bertrand Tombal disclosures: Investigator and paid advisor for Amgen, Astellas, Bayer, Ferring, Janssen, Myovant, Pfizer, and Sanofi.

Andrew Armstrong disclosures: Research and/or consulting/advising fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, DOD, Exelixis, Forma, GoodRx, Janssen, Medscape, Merck, MJH, Myovant, NIH/NCI, Novartis, Pathos, PCF/Movember, Pfizer, Telix, and Z Alpha.

Episode 2. What are the challenges of identifying and treating people with high-risk BCR? Andrew Armstrong and Bertrand Tombal consider the importance of identifying BCR, screening methods, and the role of individual patient characteristics for optimizing treatment.

This podcast series is sponsored by Astellas. This content includes information about investigational compounds that may be approved by regulatory agencies for specific indications, have been submitted to regulatory agencies for approval for specific indications, or are being studied in clinical trials and do not yet have a regulatory approval or authorization for a specific indication. Information about other potential uses of these products or investigational compounds is intended only for the purposes of medical education and is aimed at increasing the scientific knowledge of healthcare professionals (HCPs), to enhance medical practice and improve patient outcomes and should not be interpreted as intent to promote unapproved uses. Indications and availability of products discussed in this educational meeting may vary in different countries. Please refer to the local summary of product characteristics/prescribing information for details. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations, and company policies. In expert interviews, podcasts, and panel discussions, the views, thoughts, and opinions expressed belong solely to the speaker(s) and are subject to change without notice. This content is intended for HCPs only. Non-HCPs should not view this educational program and should exit the program as soon as possible.

References

  1. Freedland, 2023. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. https://www.doi.org/10.1056/NEJMoa2303974
  2. Freedland, 2007. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. https://www.doi.org/10.1200/jco.2006.08.0572
  3. Chehrazi-Raffle, 2024. Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP). https://www.doi.org/10.1200/JCO.2024.42.16_suppl.TPS5122
  4. Aggarwal, 2024. PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). https://www.doi.org/10.1200/jco.23.01157
  5. Tang, 2023. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND phase 2 randomized clinical trial. https://www.doi.org/10.1001/jamaoncol.2023.0161
  6. Abdel-Aty, 2024. 1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT). https://www.doi.org/10.1016/j.annonc.2024.08.1738
  7. Higano, 2014. Intermittent versus continuous androgen deprivation therapy. https://www.doi.org/10.6004/jnccn.2014.0074
  8. Xtandi (enzalutamide) Summary of Product Characteristics, 2025. https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf
  9. Calais da Silva, 2014. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the South European Uroncological Group. https://www.doi.org/10.1016/j.eururo.2013.03.055
  10. Salonen, 2012. The FinnProstate study VII: Intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. https://www.doi.org/10.1016/j.juro.2012.01.122
  11. Hussain, 2013. Intermittent versus continuous androgen deprivation in prostate cancer. https://www.doi.org/10.1056/NEJMoa1212299
  12. Grisay, 2024. EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors. https://www.doi.org/10.1200/JCO.2024.42.4_suppl.TPS232
  13. Armstrong, 2019. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.1200/JCO.19.00799
  14. Sweeney, 2023. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): An international, open-label, randomised, phase 3 trial. https://www.doi.org/10.1016/S1470-2045(23)00063-3
  15. Ost, 2018. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. https://www.doi.org/10.1200/jco.2017.75.4853
  16. Phillips, 2020. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. https://www.doi.org/10.1001/jamaoncol.2020.0147
  17. Shipley, 2017. Radiation with or without antiandrogen therapy in recurrent prostate cancer. https://www.doi.org/10.1056/NEJMoa1607529
  18. Morgan, 2024. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. https://www.doi.org/10.1097/ju.0000000000003892
  19. Bitting, 2021. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: The STREAM trial. https://www.doi.org/10.1016/j.euo.2020.01.005
  20. Tombal, 2025. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: Results of the EORTC 1333/PEACE-3 trial. https://www.doi.org/10.1016/j.annonc.2025.05.011
  21. Armstrong, 2025. Development and validation of an artificial intelligence digital pathology biomarker to predict benefit of long-term hormonal therapy and radiotherapy in men with high-risk prostate cancer across multiple phase III trials. https://www.doi.org/10.1200/jco.24.00365
  22. Spratt, 2023. Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase 3 trial. https://www.doi.org/10.1016/j.ijrobp.2023.04.010
  23. Nguyen, 2023. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the nrg oncology/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials. https://www.doi.org/10.1016/j.ijrobp.2022.12.035
  24. Feng, 2021. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: An ancillary study of the NRG/RTOG 9601 randomized clinical trial. https://www.doi.org/10.1001/jamaoncol.2020.7671
  25. Gallee, 1990. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. https://www.doi.org/10.1007/bf00295844
  26. Freedland, 2025. Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: A post hoc analysis of patient-reported outcomes in the EMBARK study. https://www.doi.org/10.1016/j.eururo.2025.02.006

Metastatic HSPC care: Unlocking the future1-35

 

There’s a communication, education, and just practice-change obstacle to overcome. But it’s happening. We see it in our real-world evidence more than ever.
Daniel George, MD

MA-MM-16680, February 2026


Bertrand Tombal disclosures: Investigator and paid advisor for Amgen, Astellas, Bayer, Ferring, Janssen, Myovant, Pfizer, and Sanofi.

Daniel George disclosures: Received grant/research/clinical trial support from Astellas, AstraZeneca, Bristol Myers Squibb, CORVUS, Exelixis, Janssen, Merck Sharp & Dohme, Novartis, and Pfizer; consultant/advisory boards from ABRX, Astellas, AstraZeneca, Bayer, Eisai, Exelixis, Janssen Pharmaceuticals, Merck Sharp & Dohme, MJH Life Sciences, Novartis, Pfizer, and Sumitovant Biopharma; other financial interests include American Association for Cancer Research, Bayer, Exelixis, IdeoLogy Health, Millennium Medical publishing, Clinical Advances in Hematology & Oncology, MJH Life Sciences, Pfizer, UroGPO, and UroToday (Digital Science Press).

Episode 3. How can we optimize treatment decisions to improve outcomes in mHSPC? Daniel George joins Bertrand Tombal to review the mHSPC treatment landscape, emerging assessment techniques to support clinical decisions, and how developments could support mHSPC care into the future.

This podcast series is sponsored by Astellas. This content includes information about investigational compounds that may be approved by regulatory agencies for specific indications, have been submitted to regulatory agencies for approval for specific indications, or are being studied in clinical trials and do not yet have a regulatory approval or authorization for a specific indication. Information about other potential uses of these products or investigational compounds is intended only for the purposes of medical education and is aimed at increasing the scientific knowledge of healthcare professionals (HCPs), to enhance medical practice and improve patient outcomes and should not be interpreted as intent to promote unapproved uses. Indications and availability of products discussed in this educational meeting may vary in different countries. Please refer to the local summary of product characteristics/prescribing information for details. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations, and company policies. In expert interviews, podcasts, and panel discussions, the views, thoughts, and opinions expressed belong solely to the speaker(s) and are subject to change without notice. This content is intended for HCPs only. Non-HCPs should not view this educational program and should exit the program as soon as possible.

References

  1. McNamara, 2018. The evolving landscape of metastatic hormone-sensitive prostate cancer: A critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. https://www.doi.org/10.1038/s41391-017-0014-9
  2. Clarke, 2019. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. https://www.doi.org/10.1093/annonc/mdz396
  3. Sweeney, 2015. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.1056/NEJMoa1503747
  4. James, 2015. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). https://www.doi.org/10.1016/j.eururo.2014.09.032
  5. Smani, 2025. Advances in current treatment paradigms for metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.3390/jcm14082565
  6. Davis, 2019. Enzalutamide with standard first-line therapy in metastatic prostate cancer. https://www.doi.org/10.1056/NEJMoa1903835
  7. Chi, 2019. Apalutamide for metastatic, castration-sensitive prostate cancer. https://www.doi.org/10.1056/NEJMoa1903307
  8. Saad, 2024. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. https://www.doi.org/10.1200/jco-24-01798
  9. Gotto, 2025. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer. https://www.doi.org/10.5489/cuaj.8691
  10. McManus and Armstrong, 2023. The past, present, and future of treatment intensification for metastatic hormone–sensitive prostate cancer. https://www.doi.org/10.1200/jco.23.00323
  11. Fiorica, 2025. Metastasis-directed therapy in oligometastatic prostate cancer: Biological rationale and systematic review of published data. https://www.mdpi.com/2072-6694/17/8/1256
  12. Azad, 2025. Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.1016/j.eururo.2025.01.010
  13. Cornford, 2024. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: Screening, diagnosis, and local treatment with curative intent. https://www.doi.org/10.1016/j.eururo.2024.03.027
  14. Spratt, 2021. Treating the patient and not just the cancer: Therapeutic burden in prostate cancer. https://www.doi.org/10.1038/s41391-021-00328-1
  15. Vale, 2023. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: A systematic review and meta-analysis of individual participant data from randomised trials. https://www.doi.org/10.1016/S1470-2045(23)00230-9
  16. Bryce, 2020. Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial. https://www.doi.org/10.1016/j.euo.2020.07.001
  17. Grisay, 2024. EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors. https://www.doi.org/10.1200/JCO.2024.42.4_suppl.TPS232
  18. Purysko, 2024. Not all prostate-specific membrane antigen imaging agents are created equal: Diagnostic accuracy of Ga-68 PSMA-11 PET/CT for initial and recurrent prostate cancer. https://cdn.agilitycms.com/applied-radiology/PDFs/Issues/AR_03-24_PSMA.pdf
  19. Karpinski, 2024. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: A multicentre retrospective study. https://www.doi.org/10.1016/s1470-2045(24)00326-7
  20. Vlachostergios, 2025. PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer? https://www.doi.org/10.1080/14737140.2025.2530603
  21. Dathathri, 2025. PSA secretion from single circulating tumor cells of metastatic castration-naïve prostate cancer patients. https://www.doi.org/10.1158/2767-9764.Crc-25-0158
  22. Ying, 2023. Biomarkers for prostate cancer bone metastasis detection and prediction. https://www.doi.org/10.3390/jpm13050705
  23. Mittlmeier, 2021. Feasibility of different tumor delineation approaches for (18)F-PSMA-1007 PET/CT imaging in prostate cancer patients. https://www.doi.org/10.3389/fonc.2021.663631
  24. Kim, 2024. Correlation between clinical factors and PSMA expression in prostate cancer: Variations along the disease continuum. https://jnm.snmjournals.org/content/65/supplement_2/242378
  25. Jairath, 2021. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. https://www.doi.org/10.1016/j.eururo.2020.11.021
  26. Grist, 2025. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. https://www.doi.org/10.1016/j.cell.2025.07.042
  27. Hussain, 2024. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. https://www.doi.org/10.1001/jamaoncol.2024.0591
  28. Hussain, 2023. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. https://www.doi.org/10.1200/jco.23.00041
  29. Wilson, 2022. Obesity and prostate cancer: A narrative review. https://www.doi.org/10.1016/j.critrevonc.2021.103543
  30. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, 2025. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf
  31. Fisher, 2025. Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). https://www.doi.org/10.1200/JCO.2025.43.5_suppl.20
  32. Kulasegaran and Oliveira, 2024. Metastatic castration-resistant prostate cancer: Advances in treatment and symptom management. https://www.doi.org/10.1007/s11864-024-01215-2
  33. Zattoni, 2023. Optimal combination therapy for metastatic hormone-sensitive prostate cancer: New evidence, challenges and unanswered questions. https://www.doi.org/10.1097/MOU.0000000000001124
  34. Borque-Fernando, 2023. Testosterone recovery after androgen deprivation therapy in prostate cancer: Building a predictive model. https://doi.org/10.5534/wjmh.210178
  35. Long, 2021. Decreased testosterone recovery after androgen deprivation therapy for prostate cancer. https://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=34378507

Meet the experts

Bertrand Tombal.pngBertrand Tombal, MD, PhD

Bertrand Tombal is Full Professor of Urology at the Université catholique de Louvain (UCLouvain) and Chairman of the Division of Urology at the Cliniques universitaires Saint-Luc in Brussels, Belgium. His interests include urinary oncology from both a scientific and medical perspective, with a particular focus on prostate and bladder cancer. During his PhD, he investigated the influence of growth factors on apoptosis in prostate cancer cells and the impact of apoptosis on growth factors. Tombal’s primary focus in the medical sector is the treatment of advanced prostate cancer, mainly through hormone therapy and the development of novel biologic agents, in which he conducts multiple research investigations.

Disclosures: Investigator and paid advisor for Amgen, Astellas, Bayer, Ferring, Janssen, Myovant, Pfizer, and Sanofi.

 

alt=Alicia Morgans, MD, MPH

Alicia Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist, and the Director of the Adult Survivorship Program at Dana-Farber Cancer Institute. She has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research interests include complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and she leads multiple therapeutic and quality-of-life focused clinical trials.

Disclosures: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Exelixis, Johnson & Johnson, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Sumitomo Pharma, Inc., Telix, and Tolmar.

 

Andrew Armstrong.webpAndrew Armstrong, MD, MSc

Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. As a clinical and translational investigator, he focuses on experimental therapeutics for patients with advanced genitourinary malignancies, particularly with a focus on prostate and kidney cancer and the investigation of biomarkers of response and benefit both in the laboratory and in the clinic.

Disclosures: Armstrong has received research and/or consulting/advising fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, DOD, Exelixis, Forma, GoodRx, Janssen, Medscape, Merck, MJH, Myovant, NIH/NCI, Novartis, Pathos, PCF/Movember, Pfizer, Telix, and Z Alpha.

 

Daniel George.webpDaniel George, MD

Daniel George is an Eleanor Easley Distinguished Professor in the School of Medicine, Professor of Medicine, Professor in Urology, Professor in Surgery, and Member of the Duke Cancer Institute at Duke University, Durham, North Carolina, USA. He specializes in the comprehensive care of people with urologic cancers, with a particular focus on prostate, kidney, bladder, and testicular cancer. His research interests also include the exploration of lifestyle interventions, and support mechanisms to improve overall experience for patients.

Disclosures: Received grant/research/clinical trial support from Astellas, AstraZeneca, Bristol Myers Squibb, CORVUS, Exelixis, Janssen, Merck Sharp & Dohme, Novartis, and Pfizer; consultant/advisory boards from ABRX, Astellas, AstraZeneca, Bayer, Eisai, Exelixis, Janssen Pharmaceuticals, Merck Sharp & Dohme, MJH Life Sciences, Novartis, Pfizer, and Sumitovant Biopharma; other financial interests include American Association for Cancer Research, Bayer, Exelixis, IdeoLogy Health, Millennium Medical Publishing, Clinical Advances in Hematology & Oncology, MJH Life Sciences, Pfizer, UroGPO, and UroToday (Digital Science Press).

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Astellas. Please refer to the SmPC or PI approved in your local country for further information.

MA-MM-16223, February 2026

Welcome:
Register
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event